Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: The state’s Health and Human Services Department reports the person attended the Quilt Show at the Western North Carolina Agricultural Center in late September. To date, it’s the only case of Legionnaires’ disease in an individual who didn’t attend the fair, but was at the WNC Ag Center after it ended on Sept. 15. Health officials visited the WNC Ag Center Sept. 25 and 27 and didn’t identify any sources of aerosolized water. The N.C. Department of Agriculture and Consumer Services suspended rental of the Davis Event Center after Legionella bacteria were found in one of six samples.

A: Legionnaires’ disease found in person who didn’t attend fair.
****
Q: "State lawmakers have a month before they get back to work in the 2015 legislative session and already the debate over medical marijuana has gotten into the, ahem, weeds. State Rep. Allen Peake, R-Macon serves as co-chair of a joint legislative committee that has studied whether and how to legalize the drug for certain conditions, including seizures in children. Peake has revived a bill aimed at allowing cannabis oil made from marijuana plants for treatment of certain seizure disorders and other health problems. He is finalizing that proposal, pre-filed as House Bill 1 after a similar measure fell short last session. But another committee member, state Sen. Curt Thompson, D-Tucker, is proposing a competing bill that would allow vaporized, edible or smokable marijuana. Thompson also has filed a resolution, calling for a statewide referendum on whether to authorize recreational use of the drug. Confusion about the oil form versus a smokeable drug has prompted Peake, who said he does not support expanded use, to speak out. ""We believe that the medical cannabis oil –  very low in THC, that doesn’t have a psychoactive component to it, cannot get you high – is a better approach for our citizens,"" Peake said in a press conference before a committee meeting last week. Opponents of the oil have raised safety concerns. So PolitiFact Georgia decided to take a closer look at  Peake’s contention that the oil extracted from marijuana won’t get users high. First, a reminder that the federal government still classifies marijuana as a Schedule I substance, defined as ""the most dangerous"" drug ""with no currently accepted medical use."" Despite that designation, 23 states have legalized medical marijuana, allowing access to the drug for a variety of medical conditions. Another 11 states – including neighboring Alabama, Florida, North Carolina, South Carolina and Tennessee  – have enacted laws allowing cannabis oil products for medical reasons in limited situations. The key difference in allowing the oil, supporters say, is that it is high in cannabidiol and low in tetrahydrocannabinol. Both are compounds found in the marijuana plant that act on cell receptors that control neurotransmitters in the brain and the immune system from various organs, such as the spleen. Cannabidiol, known as CBD, is an antioxidant and not psychoactive. Tetrahydrocannabinol or THC is the long-known mind-altering part of pot. Cannabis oil is made from strains of marijuana already bred to be high in CBD and low in THC. For medical use, the oil is made with less than 3 percent THC and is orally ingested. Children’s doses tend to be at 1 percent THC, or lower. Studies are scarce on the medical benefits of such a product, given the Schedule I classification. But research does show that THC is what brings both it and CBD into the brain, where CBD’s antioxidant properties are thought to protect the brain. That evidence helped the federal Department of Health and Human Services earn a patent on medical marijuana in 2003. Anecdotally, parents of children with epilepsy and other seizure diseases back up the findings, reporting marked improvement from the cannabis oil. A London drug company, GW Pharmaceuticals, has created a drug out of highly purified CBD that has shown in preclinical studies that it potentially reduce seizures. The firm is waiting on final approval from Georgia Regents University and the federal Drug Enforcement Administration to begin clinical trials in Georgia with children who have severe seizure disorders. None of the existing studies or anecdotes from parents acknowledge or report any ""high"" from cannabis oil. Even the National Institute on Drug Abuse, while acknowledging the federal government does not see marijuana as medicine, reports that CBD as a ""non-psychoactive cannabinoid"" that may prove useful in treating epilepsy as well as some inflamation disorders and mental illnesses. In other words, while the medical use of cannabis oil can be debated given the limited number of medical and clinic studies, there is some common ground on the product. Marijuana remains officially a more dangerous drug than cocaine, according to the federal government. But the main component of the plant used to make cannabis oil doesn’t have the mind-altering, munchies-inducing effect associated with street use of the plant."

A: Unlike marijuana, medical cannabis oil cannot get you high.
****
Q: She’s disappointed not to have been able to claim ultimate victory in the battle against the human immunodeficiency virus (HIV) that causes the killer disease AIDS, but also proud that in three decades, the virus has been beaten into check. While a cure for AIDS may or may not be found in her lifetime, the 68-year-old says, achieving “remission” - where infected patients control HIV in their bodies and, crucially, can come off treatment for years - is definitely within reach. “I am personally convinced that remission...is achievable. When? I don’t know. But it is feasible,” she told Reuters at her laboratory at Paris’s Pasteur Institute, where she and her mentor Luc Montagnier discovered HIV in 1983. “We have ‘proof of concept’. We have...the famous Visconti patients, treated very early on. Now it is more than 10 years since they stopped their treatment and they are still doing very well, most of them.”   Sinoussi is referring to a study group of 14 French patients known as the Visconti cohort, who started on antiretroviral treatment within 10 weeks of being infected and stayed on it for an average of three years. A decade after stopping the drugs, the majority have levels of HIV so low they are undetectable. These and other isolated cases of remission, or so-called “functional cure”, give hope to the 37 million people worldwide who, due to scientific progress, should now be able to live with, not have their lives cut short by, HIV. In developed countries at least - and in many poorer ones too - an HIV positive diagnosis is no longer an immediate death sentence, since patients can enjoy long, productive lives in decent health by taking antiretroviral drugs to control the virus. It’s a long way from the early 1980s, when Sinoussi remembers sick, dying HIV-positive patients coming to the doors of the Pasteur and pleading with scientists there for answers. “They asked us: ‘What we are going to do to cure us’,” she says. At that time, she says, she knew relatively little about HIV, but what she was sure of was that these patients would never live long enough to see a treatment developed, let alone a cure. “It was very, very hard.”  Yet this interaction with real patients, and with their doctors and later their advocates, gave Sinoussi an important insight into what was needed to make her life in science one with meaning and impact — collaboration. Working across barriers - be they scientific disciplines, cultural, religious and political divides, international borders or gender distinctions, has been and remains Sinoussi’s driving force. In her earliest days, feeling disengaged while working on her PhD and itching for action in a real-life laboratory, she hustled her way in to working at the male-dominated Pasteur Institute for free with a virologist researching links between cancers and retroviruses in mice. While viruses are her thing, she has throughout her career worked with, cajoled and learned from immunologists, cancer specialists, experts in diseases of aging, pharmaceutical companies, AIDS patients, campaigners, and even the pope. “When you work in HIV, it’s not only working in HIV, it’s working far, far beyond,” she said. Freshly armed with her Nobel award and fired up about a lack of support for proven methods of preventing HIV’s spread, Sinoussi wrote an open letter to then-Pope Benedict XVI in 2009 criticising him for saying that condoms can promote the spread of AIDS. In what was widely seen as a modification of his stance in response to such criticism, Benedict said in a book a year later that use of condoms could sometimes be justified in certain limited cases as a way to fight AIDS. Sinoussi says: “HIV has shown the way to go in the field of science. You can’t be isolated in your laboratory. You need to work with others.”  And this, she adds, is the “all together” spirit with which she advises her successors to continue after she’s gone. Many will be sad to see her leave, but she has faith that her chosen field will deliver for the people who need it. “Of course, I would love to have stopped and to see we had a vaccine against HIV and another treatment that could induce remission – but that’s life. I encourage the new generation of scientists today to continue our work. “Science never stops,” she says. “Just because a scientist stops, the science should not stop.”

A:
Science won't stop until it beats AIDS, says HIV pioneer.
****